RxDoctor Payments Data

John Sayad, MD

Cardiovascular Disease · Brooklyn, NYNPI 1831153782

Payments from drug & device makers

$163in general payments, 2019–2025

Across 7 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$73
  • Johnson & Johnson$56
  • Amarin Pharma, Inc.$18
  • Pfizer$16

What the payments were for

  • Food & beverage$163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$163 in reported general payments places this provider in the 10th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$239,978
Medicare patients
308
Services billed
2,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban352$304,105
EntrestoSacubitril/Valsartan185$166,352
XareltoRivaroxaban45$43,513
JanuviaSitagliptin Phosphate60$42,240
FarxigaDapagliflozin Propanediol57$41,651
LinzessLinaclotide61$34,911
Breo ElliptaFluticasone/Vilanterol51$23,419
JanumetSitagliptin Phos/Metformin Hcl17$15,677
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate24$14,444
VascepaIcosapent Ethyl54$13,431
BrilintaTicagrelor18$13,260
Incruse ElliptaUmeclidinium Bromide29$13,154
JardianceEmpagliflozin11$13,151
Spiriva HandihalerTiotropium Bromide15$12,454
Metoprolol Succinate690$8,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$304,105352 claims
Johnson & JohnsonXarelto$56$43,51345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →